Kaye Edward M. MD 4

What Happened

• Edward M. Kaye, MD (Director) converted/exercised derivative awards into common stock on 2026-03-15. The filing shows two conversion events: 35,500 and 26,250 shares, for a total of 61,750 shares acquired at a reported price of $0.00. Corresponding derivative entries for the same amounts were also reported as disposed (i.e., the derivative awards were settled/terminated upon conversion). No cash purchase or open-market sale of the underlying shares is reported.

Key Details

• Transaction date: 2026-03-15; Form 4 filed: 2026-03-17 (timely).
• Price: $0.00 per share (reflects RSU settlement/conversion, not a cash purchase).
• Shares acquired: 61,750 total (35,500 + 26,250). Derivative instruments of the same totals were reported as disposed upon settlement.
• Shares owned after the transactions: not specified in the provided filing.
• Footnotes: F1 = each RSU converts to one common share on settlement; F2/F3 = awards vest 1/4 annually beginning 3/15/2024 and 3/15/2025 (two separate awards/vesting schedules).
• Transaction code: M = exercise or conversion of a derivative/security right.

Context

• This was a non-cash RSU settlement (conversion of restricted stock units into common stock) rather than an open-market buy or sell. The $0.00 price reflects that RSUs settled into shares; the "disposed" derivative entries indicate the awards were terminated on settlement, not that shares were sold on the market. As a director (not a 10% owner), these filings document compensation-related equity vesting rather than an independent investment purchase.